Dr. Regis Vilchez, Chief Medical Officer of MicuRx Pharmaceuticals, presented the latest advancements of company's ...

Vertex's diverse pipeline positions it for a growth, despite challenges in launching new drugs like Casgevy and suzetrigine.

The first randomized, placebo-controlled clinical trial evaluating the impact of therapeutic monoclonal antibodies on the ...

A research team led by Prof. Patrizia Agostinis (VIB-KU Leuven) has found that melanoma cell populations protect themselves ...

NANTES, France, October 17, 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced it will be presenting its ...

Australia's Therapeutic Goods Administration (TGA) has said it won't approve Eisai and Biogen's Alzheimer's disease therapy ...

Neuroinflammation drives the progression of neurodegenerative disorders like Alzheimer's, Parkinson's, and multiple sclerosis. Targeting neuroinflammation with small molecules is promising, but ...

The first randomized, placebo-controlled clinical trial evaluating the impact of therapeutic monoclonal antibodies on the risk of developing long COVID was led by researchers at Weill Cornell Medicine ...

The biosimilar market continued to grow, with 57 approved biosimilars and 17 reference product biologics as of June 2024. Biosimilars that have seen the fastest uptake have been in oncology, ...

BMB-201 demonstrated dose-dependent efficacy in pain modelsBMB-201 demonstrated similar efficacy to morphine in several pain modelsNEW YORK, Oct.

New method cultures antitumor bacteria and enhances anticancer properties by using highly porous scaffolds of bacteria.